Adaptive, NeoGenomics partner to expand access to disease monitoring

Adaptive Biotechnologies (ADPT) and NeoGenomics (NEO) announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease, MRD, monitoring options for patients with select blood cancers. “Our partnership with NeoGenomics reflects our shared commitment to empowering oncologists and pathologists to deliver the highest quality patient care,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “As a leader in oncology testing with an extensive menu of precision oncology offerings, NeoGenomics is a natural partner for us. We are proud of this collaboration, which expands access to the valuable insights that clonoSEQ MRD results offer, ultimately helping more providers and patients benefit from knowing their MRD status.”